Description
Semaglutide 10 mg — GLP-1 Receptor Agonist for Metabolic Research
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor
agonist studied extensively in preclinical and clinical research for its effects on
glycemic control, body weight, appetite regulation, and cardiometabolic markers.
It is a synthetic analog of human GLP-1 with amino-acid substitutions and a fatty-acid side chain
to extend half-life via albumin binding.
What It Is
- Class: GLP-1 receptor agonist (incretin mimetic)
- Concept: Designed to mimic and prolong native GLP-1 signaling involved
in glucose-dependent insulin secretion and appetite regulation. - Format: Research-grade synthetic peptide supplied as a lyophilized powder.
Proposed Mechanisms (Preclinical)
Incretin & Glucose Control
- Activates GLP-1 receptors on pancreatic ?-cells to enhance
glucose-dependent insulin secretion. - Suppresses inappropriate glucagon secretion in hyperglycemic states
in experimental models. - Slows gastric emptying, contributing to lower post-prandial
glucose excursions.
Appetite, Weight & Cardiometabolic Effects
- Acts on GLP-1–responsive regions in the CNS to modulate appetite and satiety.
- Investigated for effects on body-weight reduction and fat-mass
parameters in obesity models. - Research interest in cardiometabolic markers including blood pressure,
lipids, inflammatory indices, and liver-fat content.
Selected Research Highlights
- Type 2 Diabetes Models: Semaglutide has been studied for improvements in
fasting glucose, HbA1c, and post-prandial glycemic control in preclinical and clinical
diabetes research. - Obesity & Weight Management: Trials and models report meaningful
weight loss and appetite reduction with GLP-1 receptor agonism, including
changes in caloric intake and food preference. - Cardiovascular Risk: GLP-1 RAs such as semaglutide have been investigated
for effects on major adverse cardiovascular events (MACE), blood pressure, and lipid profiles. - Liver & NAFLD/NASH: Ongoing research explores impacts on liver fat,
transaminases, and nonalcoholic fatty-liver disease–related endpoints.
Chemical & Handling Information
- Type: Synthetic GLP-1 analog (long-acting)
- Backbone: Modified human GLP-1 peptide with fatty-acid side chain for
albumin binding and prolonged half-life (exact modification per specification/lot) - Appearance: White to off-white lyophilized powder
Specifications
- Peptide: Semaglutide
- Amount: 10 mg per vial
- Form: Lyophilized powder
- Purity: ?99% (HPLC); COA per lot available
- Packaging: Sealed vials suitable for standard laboratory handling
Storage & Stability
- Store lyophilized vials in a cool, dry place, protected from light.
- Refrigeration or freezing of the lyophilized peptide is recommended for extended stability,
according to laboratory SOPs. - After reconstitution, store at 2–8 °C for short-term use.
- For long-term storage, aliquot and freeze at ?20 °C or below; avoid repeated freeze–thaw cycles.
Reviews
There are no reviews yet.